Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion
Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for over $2 billion, according to The Wall Street Journal. The deal may include additional milestone-based payments and would strengthen Lilly's cancer portfolio. The acquisition is part of Lilly's broader strategy to expand into various therapeutic areas, including cancer and gene-editing technologies.
Tickers: $LLY
Topics: acquisition biotechnology CAR-T therapy Eli Lilly Kelonia Therapeutics pharmaceutical industry